Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma

SIMPLE SUMMARY: Rhabdomyosarcoma (RMS) accounts for more than 50% of all soft tissue sarcomas in childhood and adolescence. Despite progress and intensified multimodality treatment, prognoses are extremely poor with an overall survival rate of approximately 20% in the advanced stage. Therefore, ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Alijaj, Nagjie, Moutel, Sandrine, Gouveia, Zelia L., Gray, Maxim, Roveri, Maurizio, Dzhumashev, Dzhangar, Weber, Florian, Meier, Gianmarco, Luciani, Paola, Rössler, Jochen K., Schäfer, Beat W., Perez, Franck, Bernasconi, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696840/
https://www.ncbi.nlm.nih.gov/pubmed/33182650
http://dx.doi.org/10.3390/cancers12113313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696840/
https://www.ncbi.nlm.nih.gov/pubmed/33182650
http://dx.doi.org/10.3390/cancers12113313

Ejemplares similares